Evidence mapPaperPMID 40565232Full record

ReviewInternational journal of molecular sciences2025

Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions.

Meizhai Guo, Bingyi Zheng, Xiaoling Zeng, Xueting Wang, Chi-Meng Tzeng

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meizhai GuoTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Bingyi ZhengTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Xiaoling ZengTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Xueting WangTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Chi-Meng TzengTranslational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0000-0003-3490-2574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular therapeutics, encompassing stem cell-based regeneration and engineered immune cell platforms, have demonstrated efficacy in treating degenerative diseases, immune-related diseases, and oncology. However, low engraftment rates and limited long-term efficacy remain critical translational barriers. This review compiled clinical projects on cell therapy in China over the past five years (over 1200 patients across 172 clinical trials) to highlight its rapid development in recent years and illustrate the directions of indications for application. This review also analyzes published clinical achievements all over the world, revealing significant therapeutic improvements in degenerative disorders (40-60% improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and oncology (78% ctDNA clearance,

Indexed as

Cell- and Tissue-Based TherapyStem Cell TransplantationAnimalsClinical Trials as TopicHumansMedicine, Chinese TraditionalcancerCAR-Tcellular therapeuticsdegeneration diseasesMSCtraditional Chinese medicine

Identifiers

PMID40565232
PMCPMC12193569

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.